Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab with or without anti-LAG-3 and anti-TIM-3 for first-line PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck
NL-OMON53614Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing retifanlimab + placebo + placebo, retifanlimab + INCAGN02385 + placebo and retifanlimab + INCAGN02385 + INCAGN02390 (3 arms). Primary endpoint: Progression-free survival. Started Aug 2022; status: active, not recruiting.
02
Drugs
retifanlimabtuparstobartverzistobart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON53614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53614.